Molecular Diagnosis of Gall Bladder Cancer

  • Rajani Rai
  • Saumyak Gosai
  • Chinthalapally V. Rao
  • Vishal ChandraEmail author


Worldwide, gallbladder cancer (GBC) is comparatively rare but highly fatal and the most common biliary tree malignancy with gender and geographical-specific predilections that associate with the incidence of cholelithiasis. Morphological feature and anatomic location of gallbladder along with asymptomatic and aggressive nature of the disease progression are ascribed to advance stage diagnosis, poor prognosis thereby compromising GBC patient’s survival rate. Only 20% of GBC patients are diagnosed early with cancer progression limited to gallbladder while rest of the patients are diagnosed with metastasis to adjacent or distant organs. Currently, the available treatment option includes surgical removal of the non-metastatic and small-sized tumor or radiation therapy and/or chemotherapy in advanced stages with various side effects accounting for global health burden. With the recent advancement in better understanding of GBC pathogenesis, several markers have been proposed and evaluated for diagnostic efficiency in GBC. However, none of the markers identified so far has been developed for routine screening examination for GBC and still, there is lack of appropriate molecular diagnostic markers for its early detection and improve prognoses. Till today the complete treatment of GBCs remains unsatisfactory and a major challenge facing a bottleneck. In this chapter, we will focus on the GBC pathogenesis, available diagnostic methods and recent development in the molecular diagnostic methods that may provide future research directions for early detection of this deadly disease.


  1. 1.
    Sharma A, et al. Gallbladder cancer epidemiology, pathogenesis and molecular genetics: recent update. World J Gastroenterol. 2017;23(22):3978–98.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer. 2006;118(7):1591–602.PubMedCrossRefGoogle Scholar
  3. 3.
    Wernberg JA, Lucarelli DD. Gallbladder cancer. Surg Clin North Am. 2014;94(2):343–60.PubMedCrossRefGoogle Scholar
  4. 4.
    Kumar JR, et al. An objective assessment of demography of gallbladder cancer. J Surg Oncol. 2006;93(8):610–4.PubMedCrossRefGoogle Scholar
  5. 5.
    Gabbi C, et al. Estrogen-dependent gallbladder carcinogenesis in LXRbeta−/− female mice. Proc Natl Acad Sci U S A. 2010;107(33):14763–8.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014;6:99–109.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Lai CH, Lau WY. Gallbladder cancer—a comprehensive review. Surgeon. 2008;6(2):101–10.PubMedCrossRefGoogle Scholar
  8. 8.
    Tomita K, et al. Long-term survival of a recurrent gallbladder carcinoma patient with lymph node and peritoneal metastases after multidisciplinary treatments: a case report. Surg Case Rep. 2016;2(1):12.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Rai R, et al. A multiple interaction analysis reveals ADRB3 as a potential candidate for gallbladder cancer predisposition via a complex interaction with other candidate gene variations. Int J Mol Sci. 2015;16(12):28038–49.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Dwivedi AN, Jain S, Dixit R. Gall bladder carcinoma: aggressive malignancy with protean loco-regional and distant spread. World J Clin Cases. 2015;3(3):231–44.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Misra S, et al. Carcinoma of the gallbladder. Lancet Oncol. 2003;4(3):167–76.PubMedCrossRefGoogle Scholar
  12. 12.
    Shrikhande SV, et al. Cholelithiasis in gallbladder cancer: coincidence, cofactor, or cause! Eur J Surg Oncol. 2010;36(6):514–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Nervi F, Duarte I, Gómez G, Rodríguez G, Del Pino G, Ferrerio O, et al. Frequency of gallbladder cancer in Chile, a high-risk area. Int J Cancer. 1988;41:657–60.PubMedCrossRefGoogle Scholar
  14. 14.
    Hamdani NH, et al. Clinicopathological study of gall bladder carcinoma with special reference to gallstones: our 8-year experience from eastern India. Asian Pac J Cancer Prev. 2012;13(11):5613–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Lowenfels AB, et al. Gallstone growth, size, and risk of gallbladder cancer: an interracial study. Int J Epidemiol. 1989;18(1):50–4.PubMedCrossRefGoogle Scholar
  16. 16.
    Roa I, et al. Gallstones and gallbladder cancer-volume and weight of gallstones are associated with gallbladder cancer: a case-control study. J Surg Oncol. 2006;93(8):624–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Biswas PK. Carcinoma gallbladder. Mymensingh Med J. 2010;19(3):477–81.PubMedGoogle Scholar
  18. 18.
    Espinoza JA, et al. The inflammatory inception of gallbladder cancer. Biochim Biophys Acta. 2016;1865(2):245–54.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Tazuma S, Kajiyama G. Carcinogenesis of malignant lesions of the gall bladder. The impact of chronic inflammation and gallstones. Langenbeck’s Arch Surg. 2001;386(3):224–9.CrossRefGoogle Scholar
  20. 20.
    Li Y, Zhang J, Ma H. Chronic inflammation and gallbladder cancer. Cancer Lett. 2014;345(2):242–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Sharma V, et al. Role of bile bacteria in gallbladder carcinoma. Hepato-Gastroenterology. 2007;54(78):1622–5.PubMedGoogle Scholar
  22. 22.
    Andia ME, et al. Geographic variation of gallbladder cancer mortality and risk factors in Chile: a population-based ecologic study. Int J Cancer. 2008;123(6):1411–6.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Tewari M, Mishra RR, Shukla HS. Salmonella typhi and gallbladder cancer: report from an endemic region. Hepatobiliary Pancreat Dis Int. 2010;9(5):524–30.PubMedGoogle Scholar
  24. 24.
    Tyagi BB, Manoharan N, Raina V. Risk factors for gallbladder cancer: a population based case-control study in Delhi. Indian J Med Pediatr Oncol. 2008;29:16–26.CrossRefGoogle Scholar
  25. 25.
    Shukla VK, et al. Carcinoma of the gallbladder—is it a sequel of typhoid? Dig Dis Sci. 2000;45(5):900–3.PubMedCrossRefGoogle Scholar
  26. 26.
    Di Domenico EG, et al. Biofilm producing Salmonella typhi: chronic colonization and development of gallbladder cancer. Int J Mol Sci. 2017;18(9):1887.PubMedCentralCrossRefGoogle Scholar
  27. 27.
    Prieto AI, Ramos-Morales F, Casadesus J. Repair of DNA damage induced by bile salts in Salmonella enterica. Genetics. 2006;174(2):575–84.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Rai A, Mohapatra SC, Shukla HS. A review of association of dietary factors in gallbladder cancer. Indian J Cancer. 2004;41(4):147–51.PubMedGoogle Scholar
  29. 29.
    Makiuchi T, et al. The relationship between vegetable/fruit consumption and gallbladder/bile duct cancer: a population-based cohort study in Japan. Int J Cancer. 2017;140(5):1009–19.PubMedCrossRefGoogle Scholar
  30. 30.
    Panda D, et al. Gall bladder cancer and the role of dietary and lifestyle factors: a case-control study in a North Indian population. Eur J Cancer Prev. 2013;22(5):431–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Li L, et al. Overweight, obesity and the risk of gallbladder and extrahepatic bile duct cancers: a meta-analysis of observational studies. Obesity (Silver Spring). 2016;24(8):1786–802.CrossRefGoogle Scholar
  32. 32.
    Tan W, et al. Body mass index and risk of gallbladder cancer: systematic review and meta-analysis of observational studies. Nutrients. 2015;7(10):8321–34.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Wang F, Wang B, Qiao L. Association between obesity and gallbladder cancer. Front Biosci (Landmark Ed). 2012;17:2550–8.CrossRefGoogle Scholar
  34. 34.
    Larsson SC, Wolk A. Obesity and the risk of gallbladder cancer: a meta-analysis. Br J Cancer. 2007;96(9):1457–61.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Liu H, et al. Body mass index can increase the risk of gallbladder cancer: a meta-analysis of 14 cohort studies. Med Sci Monit Basic Res. 2016;22:146–55.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Hsing AW, et al. Family history of gallstones and the risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China. Int J Cancer. 2007;121(4):832–8.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Fernandez E, et al. Family history and the risk of liver, gallbladder, and pancreatic cancer. Cancer Epidemiol Biomark Prev. 1994;3(3):209–12.Google Scholar
  38. 38.
    Rai R, et al. p53: its alteration and gallbladder cancer. Eur J Cancer Prev. 2011;20(2):77–85.PubMedCrossRefGoogle Scholar
  39. 39.
    Wistuba II, et al. p53 protein overexpression in gallbladder carcinoma and its precursor lesions: an immunohistochemical study. Hum Pathol. 1996;27(4):360–5.PubMedCrossRefGoogle Scholar
  40. 40.
    Rashid A, et al. K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China. Clin Cancer Res. 2002;8(10):3156–63.PubMedGoogle Scholar
  41. 41.
    Wistuba II, et al. Allele-specific mutations involved in the pathogenesis of endemic gallbladder carcinoma in Chile. Cancer Res. 1995;55(12):2511–5.PubMedGoogle Scholar
  42. 42.
    Singh MK, et al. Mutational spectrum of K-ras oncogene among Indian patients with gallbladder cancer. J Gastroenterol Hepatol. 2004;19(8):916–21.PubMedCrossRefGoogle Scholar
  43. 43.
    Saetta AA. K-ras, p53 mutations, and microsatellite instability (MSI) in gallbladder cancer. J Surg Oncol. 2006;93(8):644–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Roa I, et al. Preneoplastic lesions in gallbladder cancer. J Surg Oncol. 2006;93(8):615–23.PubMedCrossRefGoogle Scholar
  45. 45.
    Segovia Lohse HA, Cuenca Torres OM. Prevalence and sequence of metaplasia-dysplasia-carcinoma of the gallbladder. A single centre retrospective study. Cir Esp. 2013;91(10):672–5.PubMedCrossRefGoogle Scholar
  46. 46.
    Itoi T, et al. APC, K-ras codon 12 mutations and p53 gene expression in carcinoma and adenoma of the gall-bladder suggest two genetic pathways in gall-bladder carcinogenesis. Pathol Int. 1996;46(5):333–40.PubMedCrossRefGoogle Scholar
  47. 47.
    Kozuka S, et al. Relation of adenoma to carcinoma in the gallbladder. Cancer. 1982;50(10):2226–34.PubMedCrossRefGoogle Scholar
  48. 48.
    Wan X, et al. Clinicopathological features of gallbladder papillary adenocarcinoma. Medicine (Baltimore). 2014;93(27):e131.CrossRefGoogle Scholar
  49. 49.
    Dursun N, et al. Mucinous carcinomas of the gallbladder: clinicopathologic analysis of 15 cases identified in 606 carcinomas. Arch Pathol Lab Med. 2012;136(11):1347–58.PubMedCrossRefGoogle Scholar
  50. 50.
    Singh SK, et al. Mucinous carcinoma of the gall bladder—an incidental diagnosis of a rare variant. J Cancer Res Ther. 2015;11(4):1045.PubMedGoogle Scholar
  51. 51.
    Maharaj R, et al. A case report of the clear cell variant of gallbladder carcinoma. Int J Surg Case Rep. 2017;32:36–9.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Zhang C, et al. A clear cell adenocarcinoma of the gallbladder with hepatoid differentiation: case report and review of literature. Onco Targets Ther. 2016;9:5797–802.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Oohashi Y, et al. Adenosquamous carcinoma of the gallbladder warrants resection only if curative resection is feasible. Cancer. 2002;94(11):3000–5.PubMedCrossRefGoogle Scholar
  54. 54.
    Rustagi T, Rai M, Menon M. Ruptured adenosquamous cell carcinoma of the gallbladder: case report and review of literature. Gastrointest Cancer Res. 2011;4(1):29–32.PubMedPubMedCentralGoogle Scholar
  55. 55.
    Bazan F, et al. Metastatic gallbladder adenocarcinoma with signet-ring cells: a case report. J Med Case Rep. 2011;5:458.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Ahmad Z, Qureshi A. Primary signet ring cell carcinoma of gall bladder: report of an extremely rare histological type of primary gall bladder carcinoma. BMJ Case Rep. 2010;2010:bcr0420091782.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Guo KJ, Yamaguchi K, Enjoji M. Undifferentiated carcinoma of the gallbladder. A clinicopathologic, histochemical, and immunohistochemical study of 21 patients with a poor prognosis. Cancer. 1988;61(9):1872–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Eltawil KM, et al. Neuroendocrine tumors of the gallbladder: an evaluation and reassessment of management strategy. J Clin Gastroenterol. 2010;44(10):687–95.PubMedGoogle Scholar
  59. 59.
    Monier A, et al. Neuroendocrine tumor of the gallbladder. Pol J Radiol. 2015;80:228–31.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Mezi S, et al. Neuroendocrine tumors of the gallbladder: a case report and review of the literature. J Med Case Rep. 2011;5:334.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Carrera C, Kunk P, Rahma O. Small cell carcinoma of the gallbladder: case report and comprehensive analysis of published cases. J Oncol. 2015;2015:304909.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Adachi T, et al. Gallbladder small cell carcinoma: a case report and literature review. Surg Case Rep. 2016;2(1):71.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Lee H, Choi HJ, Park IY. Small cell carcinoma of the gallbladder: a case report. Ann Hepatobiliary Pancreat Surg. 2017;21(3):168–71.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Al-Daraji WI, et al. Primary gallbladder sarcoma: a clinicopathologic study of 15 cases, heterogeneous sarcomas with poor outcome, except pediatric botryoid rhabdomyosarcoma. Am J Surg Pathol. 2009;33(6):826–34.PubMedCrossRefGoogle Scholar
  65. 65.
    Husain EA, et al. Gallbladder sarcoma: a clinicopathological study of seven cases from the UK and Austria with emphasis on morphological subtypes. Dig Dis Sci. 2009;54(2):395–400.PubMedCrossRefGoogle Scholar
  66. 66.
    Miller G, Jarnagin WR. Gallbladder carcinoma. Eur J Surg Oncol. 2008;34(3):306–12.PubMedCrossRefGoogle Scholar
  67. 67.
    Gourgiotis S, et al. Gallbladder cancer. Am J Surg. 2008;196(2):252–64.PubMedCrossRefGoogle Scholar
  68. 68.
    Yang XW, et al. The prognostic importance of jaundice in surgical resection with curative intent for gallbladder cancer. BMC Cancer. 2014;14:652.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Feng FL, et al. Role of radical resection in patients with gallbladder carcinoma and jaundice. Chin Med J. 2012;125(5):752–6.PubMedGoogle Scholar
  70. 70.
    Wang YF, et al. Combined detection tumor markers for diagnosis and prognosis of gallbladder cancer. World J Gastroenterol. 2014;20(14):4085–92.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Rana S, et al. Evaluation of CA 242 as a tumor marker in gallbladder cancer. J Gastrointest Cancer. 2012;43(2):267–71.PubMedCrossRefGoogle Scholar
  72. 72.
    Chaube A, et al. CA 125: a potential tumor marker for gallbladder cancer. J Surg Oncol. 2006;93(8):665–9.PubMedCrossRefGoogle Scholar
  73. 73.
    Xu XS, et al. Model based on alkaline phosphatase and gamma-glutamyltransferase for gallbladder cancer prognosis. Asian Pac J Cancer Prev. 2015;16(15):6255–9.PubMedCrossRefGoogle Scholar
  74. 74.
    Ong SL, et al. Ten-year experience in the management of gallbladder cancer from a single hepatobiliary and pancreatic centre with review of the literature. HPB (Oxford). 2008;10(6):446–58.CrossRefGoogle Scholar
  75. 75.
    Singh TD, et al. Quantitative assessment of expression of lactate dehydrogenase and its isoforms 3 and 4 may serve as useful indicators of progression of gallbladder cancer: a pilot study. Indian J Clin Biochem. 2011;26(2):146–53.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Singh TD, et al. The liver function test enzymes and glucose level are positively correlated in gallbladder cancer: a cancer registry data analysis from north central India. Indian J Cancer. 2012;49(1):125–36.PubMedCrossRefGoogle Scholar
  77. 77.
    Oikarinen H. Diagnostic imaging of carcinomas of the gallbladder and the bile ducts. Acta Radiol. 2006;47(4):345–58.PubMedCrossRefGoogle Scholar
  78. 78.
    Recio-Boiles A, Babiker HM. Cancer, gallbladder. Treasure Island: StatPearls; 2018.Google Scholar
  79. 79.
    Inui K, Yoshino J, Miyoshi H. Diagnosis of gallbladder tumors. Intern Med. 2011;50(11):1133–6.PubMedCrossRefGoogle Scholar
  80. 80.
    Kim HJ, et al. Diagnostic role of endoscopic ultrasonography-guided fine needle aspiration of gallbladder lesions. Hepato-Gastroenterology. 2012;59(118):1691–5.PubMedGoogle Scholar
  81. 81.
    Kumaran V, et al. The role of dual-phase helical CT in assessing resectability of carcinoma of the gallbladder. Eur Radiol. 2002;12(8):1993–9.PubMedCrossRefGoogle Scholar
  82. 82.
    Tan CH, Lim KS. MRI of gallbladder cancer. Diagn Interv Radiol. 2013;19(4):312–9.PubMedGoogle Scholar
  83. 83.
    Andren-Sandberg A. Diagnosis and management of gallbladder cancer. N Am J Med Sci. 2012;4(7):293–9.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Vijayakumar A, et al. Early diagnosis of gallbladder carcinoma: an algorithm approach. ISRN Radiol. 2013;2013:239424.PubMedGoogle Scholar
  85. 85.
    Kapoor A, Kapoor A, Mahajan G. Differentiating malignant from benign thickening of the gallbladder wall by the use of acoustic radiation force impulse elastography. J Ultrasound Med. 2011;30(11):1499–507.PubMedCrossRefGoogle Scholar
  86. 86.
    Kumar R, et al. Role of 18F-FDG PET/CT in detecting recurrent gallbladder carcinoma. Clin Nucl Med. 2012;37(5):431–5.PubMedCrossRefGoogle Scholar
  87. 87.
    Ramos-Font C, et al. Ability of FDG-PET/CT in the detection of gallbladder cancer. J Surg Oncol. 2014;109(3):218–24.PubMedCrossRefGoogle Scholar
  88. 88.
    Hennedige TP, Neo WT, Venkatesh SK. Imaging of malignancies of the biliary tract–an update. Cancer Imaging. 2014;14:14.PubMedPubMedCentralGoogle Scholar
  89. 89.
    De Moura DTH, et al. Endoscopic retrograde cholangiopancreatography versus endoscopic ultrasound for tissue diagnosis of malignant biliary stricture: systematic review and meta-analysis. Endosc Ultrasound. 2018;7(1):10–9.PubMedCrossRefGoogle Scholar
  90. 90.
    Wang SN, et al. Aberrant p53 expression and the development of gallbladder carcinoma and adenoma. Kaohsiung J Med Sci. 2006;22(2):53–9.PubMedCrossRefGoogle Scholar
  91. 91.
    Asai T, et al. High frequency of TP53 but not K-ras gene mutations in Bolivian patients with gallbladder cancer. Asian Pac J Cancer Prev. 2014;15(13):5449–54.PubMedCrossRefGoogle Scholar
  92. 92.
    Maurya SK, et al. Genetic aberrations in gallbladder cancer. Surg Oncol. 2012;21(1):37–43.PubMedCrossRefGoogle Scholar
  93. 93.
    Kumari N, et al. Role of C-erbB2 expression in gallbladder cancer. Indian J Pathol Microbiol. 2012;55(1):75–9.PubMedCrossRefGoogle Scholar
  94. 94.
    Pujani M, et al. Expression of human epidermal growth factor receptor (Her 2/neu) and proliferative marker Ki-67: association with clinicopathological parameters in gallbladder carcinoma. Asian Pac J Cancer Prev. 2016;17(8):3903–9.PubMedGoogle Scholar
  95. 95.
    Kanthan R, et al. Gallbladder cancer in the 21st century. J Oncol. 2015;2015:967472.PubMedPubMedCentralCrossRefGoogle Scholar
  96. 96.
    Ma HB, et al. Association of cyclin D1, p16 and retinoblastoma protein expressions with prognosis and metastasis of gallbladder carcinoma. World J Gastroenterol. 2005;11(5):744–7.PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Srivastava V, et al. Cyclin D1, retinoblastoma and p16 protein expression in carcinoma of the gallbladder. Asian Pac J Cancer Prev. 2013;14(5):2711–5.PubMedCrossRefGoogle Scholar
  98. 98.
    Kim K, et al. Expression of cell cycle-related proteins, p16, p53 and p63 as important prognostic markers in gallbladder adenocarcinoma. Pathol Oncol Res. 2014;20(2):409–15.PubMedCrossRefGoogle Scholar
  99. 99.
    Roa JC, et al. Inactivation of CDKN2A gene (p16) in gallbladder carcinoma. Rev Med Chil. 2004;132(11):1369–76.PubMedGoogle Scholar
  100. 100.
    Feng Z, et al. The risk factor of gallbladder cancer: hyperplasia of mucous epithelium caused by gallstones associates with p16/CyclinD1/CDK4 pathway. Exp Mol Pathol. 2011;91(2):569–77.PubMedCrossRefGoogle Scholar
  101. 101.
    Yao H, et al. The role of annexin A4 in cancer. Front Biosci (Landmark Ed). 2016;21:949–57.CrossRefGoogle Scholar
  102. 102.
    Huang HL, et al. Proteomic identification of tumor biomarkers associated with primary gallbladder cancer. World J Gastroenterol. 2014;20(18):5511–8.PubMedPubMedCentralCrossRefGoogle Scholar
  103. 103.
    Yao HS, et al. Annexin A4-nuclear factor-kappaB feedback circuit regulates cell malignant behavior and tumor growth in gallbladder cancer. Sci Rep. 2016;6:31056.PubMedPubMedCentralCrossRefGoogle Scholar
  104. 104.
    Jagannath P, Callery M. Molecular prognostic markers in gallbladder carcinoma. HPB (Oxford). 2012;14(9):571–2.CrossRefGoogle Scholar
  105. 105.
    Nagano M, et al. Nuclear expression of thioredoxin-1 in the invasion front is associated with outcome in patients with gallbladder carcinoma. HPB (Oxford). 2012;14(9):573–82.CrossRefGoogle Scholar
  106. 106.
    Wu K, et al. ADAM-17 over-expression in gallbladder carcinoma correlates with poor prognosis of patients. Med Oncol. 2011;28(2):475–80.PubMedCrossRefGoogle Scholar
  107. 107.
    Puhalla H, et al. E-cadherin and beta-catenin expression in normal, inflamed and cancerous gallbladder tissue. Anticancer Res. 2005;25(6B):4249–54.PubMedGoogle Scholar
  108. 108.
    Priya TP, et al. Role of E-cadherin gene in gall bladder cancer and its precursor lesions. Virchows Arch. 2010;456(5):507–14.PubMedCrossRefGoogle Scholar
  109. 109.
    Yi S, et al. N-cadherin and P-cadherin are biomarkers for invasion, metastasis, and poor prognosis of gallbladder carcinomas. Pathol Res Pract. 2014;210(6):363–8.PubMedCrossRefGoogle Scholar
  110. 110.
    Nakamura T, et al. Prognostic significance of S100A4 expression in gallbladder cancer. Int J Oncol. 2002;20(5):937–41.PubMedGoogle Scholar
  111. 111.
    Luo W, et al. Clinical correlation of calpain-1 and glypican-3 expression with gallbladder carcinoma. Oncol Lett. 2016;11(2):1345–52.PubMedPubMedCentralCrossRefGoogle Scholar
  112. 112.
    Saranga Bharathi R, et al. Female sex hormone receptors in gallbladder cancer. J Gastrointest Cancer. 2015;46(2):143–8.PubMedCrossRefGoogle Scholar
  113. 113.
    Gupta P, et al. Expression and clinicopathological significance of estrogen and progesterone receptors in gallbladder cancer. Gastrointest Cancer Res. 2012;5(2):41–7.PubMedPubMedCentralGoogle Scholar
  114. 114.
    Baskaran V, et al. Do the progesterone receptors have a role to play in gallbladder cancer? Int J Gastrointest Cancer. 2005;35(1):61–8.PubMedCrossRefGoogle Scholar
  115. 115.
    Park JS, et al. Estrogen receptor alpha, estrogen receptor beta, and progesterone receptor as possible prognostic factor in radically resected gallbladder carcinoma. J Surg Res. 2009;152(1):104–10.PubMedCrossRefGoogle Scholar
  116. 116.
    Sumi K, et al. Loss of estrogen receptor beta expression at cancer front correlates with tumor progression and poor prognosis of gallbladder cancer. Oncol Rep. 2004;12(5):979–84.PubMedGoogle Scholar
  117. 117.
    Chandra V, et al. MicroRNA aberrations: an emerging field for gallbladder cancer management. World J Gastroenterol. 2016;22(5):1787–99.PubMedPubMedCentralCrossRefGoogle Scholar
  118. 118.
    Li G, Pu Y. MicroRNA signatures in total peripheral blood of gallbladder cancer patients. Tumour Biol. 2015;36(9):6985–90.PubMedCrossRefGoogle Scholar
  119. 119.
    Pang Q, et al. Platelet to lymphocyte ratio as a novel prognostic tool for gallbladder carcinoma. World J Gastroenterol. 2015;21(21):6675–83.PubMedPubMedCentralCrossRefGoogle Scholar
  120. 120.
    Zhang L, et al. Prognostic significance of neutrophil to lymphocyte ratio in patients with gallbladder carcinoma. HPB (Oxford). 2016;18(7):600–7.CrossRefGoogle Scholar
  121. 121.
    Zhang Y, et al. Prognostic significance of preoperative neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in patients with gallbladder carcinoma. Clin Transl Oncol. 2015;17(10):810–8.PubMedCrossRefGoogle Scholar
  122. 122.
    Saqib R, et al. Prognostic significance of pre-operative inflammatory markers in resected gallbladder cancer: a systematic review. ANZ J Surg. 2018;88(6):554–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Rajani Rai
    • 1
  • Saumyak Gosai
    • 1
    • 2
  • Chinthalapally V. Rao
    • 3
  • Vishal Chandra
    • 1
    Email author
  1. 1.Department of Obstetrics and GynecologyUniversity of Oklahoma Health Sciences CenterOklahoma CityUSA
  2. 2.McAllen Family Medicine Residency ProgramMcAllenUSA
  3. 3.Hematology/Oncology Section, Department of MedicineCenter for Cancer Prevention and Drug Development, Stephenson Cancer Center (SCC), University of Oklahoma Health Sciences Center (OUHSC)Oklahoma CityUSA

Personalised recommendations